CTLT vs. RDY, ELAN, LEGN, SRPT, UTHR, CERE, ASND, VKTX, ITCI, and VTRS
Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), and Viatris (VTRS). These companies are all part of the "pharmaceutical preparations" industry.
Catalent (NYSE:CTLT) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
Catalent has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Dr. Reddy's Laboratories has lower revenue, but higher earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Dr. Reddy's Laboratories has a net margin of 19.97% compared to Catalent's net margin of -26.61%. Dr. Reddy's Laboratories' return on equity of 21.27% beat Catalent's return on equity.
Catalent received 323 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. However, 59.25% of users gave Dr. Reddy's Laboratories an outperform vote while only 59.20% of users gave Catalent an outperform vote.
In the previous week, Catalent had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 3 mentions for Catalent and 1 mentions for Dr. Reddy's Laboratories. Catalent's average media sentiment score of 1.39 beat Dr. Reddy's Laboratories' score of 0.68 indicating that Catalent is being referred to more favorably in the media.
14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.3% of Catalent shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Catalent currently has a consensus price target of $53.14, suggesting a potential downside of 1.60%. Dr. Reddy's Laboratories has a consensus price target of $81.00, suggesting a potential upside of 14.18%. Given Dr. Reddy's Laboratories' higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Catalent.
Summary
Dr. Reddy's Laboratories beats Catalent on 11 of the 18 factors compared between the two stocks.
Get Catalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalent Competitors List
Related Companies and Tools
